Category: Press Releases
June 19, 2020 | Press Releases
Jackie Schumacher Joins Rallybio to Lead Global Regulatory Affairs
NEW HAVEN, Conn., June 19, 2020 – Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced the hiring of Jackie Schumacher to lead Global Regulatory Affairs. In this role, Ms. Schumacher will have responsibility for Rallybio’s global regulatory strategy and operations across the portfolio, including the Company’s lead product candidate, RLYB211, which is in development for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
May 28, 2020 | Press Releases
Rallybio Further Broadens Drug Development Capabilities with Addition of Róisín Armstrong, PhD
NEW HAVEN, Conn., May 28, 2020 – Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced the hiring of Róisín Armstrong, PhD. Dr. Armstrong, a seasoned drug developer, will head the development of the Company’s lead program, RLYB211. RLYB211, a plasma-derived hyperimmune globulin, is in development for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
May 19, 2020 | Press Releases
Rallybio Completes $145 Million Series B Financing and Announces Plans to Advance Lead Product Candidate into the Clinic in 2H 2020
— Financing Led by Pivotal bioVenture Partners
May 5, 2020 | Press Releases
Rachael Alford, PhD Joins Rallybio to Lead CMC Operations
NEW HAVEN, Conn., May 5, 2020 – Rallybio LLC, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced the hiring of Rachael Alford, PhD to lead the Company’s Chemistry, Manufacturing and Controls (CMC) operations. In this role, Dr. Alford will have responsibility for overseeing the process development, analytical and formulation development, and manufacturing and supply chain of Rallybio’s product candidates.
April 7, 2020 | Press Releases
Michael Greco, JD Joins Rallybio to Head Legal Operations
NEW HAVEN, Conn., April 7, 2020 – Rallybio LLC, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced the hiring of Michael Greco, JD to lead the Company’s legal function. In this role, Mr. Greco will have responsibility for Rallybio’s legal, intellectual property, compliance and governance activities.
October 31, 2019 | Press Releases
Rallybio Expands Leadership Team and Strengthens Drug Acquisition Capabilities
FARMINGTON, Conn., October 31, 2019 – Rallybio LLC, a development-stage biotechnology company, today announced that it has further expanded its drug acquisition and development capabilities with the addition of Amanda Hayward, PhD and Lisa Sinclair, to the Rallybio team. Specifically, Dr. Hayward will focus on further building Rallybio’s portfolio and Ms. Sinclair will be focused on new product commercial planning including diagnostic and patient access approaches to support the portfolio. These leadership appointments further advance Rallybio’s mission to identify and accelerate the development of transformative breakthrough therapies for patients with severe and rare disorders. Amanda Hayward, PhD
September 12, 2019 | Press Releases
Rallybio Broadens Team Capabilities with Addition of Douglas Sheridan, PhD
FARMINGTON, Conn., September 12, 2019 – Rallybio LLC, a development-stage biotechnology company, today announced that it has broadened its drug development capabilities with the addition of Douglas Sheridan, PhD. Dr. Sheridan, a seasoned R&D leader, has significant drug development experience, including discovery, strategic planning and clinical program management. He will help advance Rallybio’s mission to identify and accelerate the development of transformative breakthrough therapies for patients with severe and rare disorders.
August 8, 2019 | Press Releases
Rallybio Expands Drug Development Team with Addition of Ann Willauer, PMP
Rallybio Expands Drug Development Team with Addition of Ann Willauer, PMP
January 3, 2019 | Press Releases
Rallybio Further Strengthens Leadership Team with Addition of Steven Ryder
R&D Executive with Proven Track Record in the Biopharmaceutical Industry
October 2, 2018 | Press Releases
FierceBiotech Names Rallybio as One of its “Fierce 15” Biotech Companies of 2018
Award recognizes Rallybio as being among “the most promising private biotech startups”